Literature DB >> 12232676

Differences in sialic acid residues among bone alkaline phosphatase isoforms: a physical, biochemical, and immunological characterization.

P Magnusson1, J R Farley.   

Abstract

High-performance liquid chromatography (HPLC) separates three human bone alkaline phosphatase (BALP) isoforms in serum; two major BALP isoforms, B1 and B2, and a minor fraction, B/I, which is composed on average of 70% bone and 30% intestinal ALP. The current studies were intended to identify an in vitro source of the BALP isoforms for physical, biochemical, and immunological characterizations. The three BALP isoforms were identified in extracts of human osteosarcoma (SaOS-2) cells, by HPLC, after separation by anion-exchange chromatography. All three BALP isoforms were similar with respect to freeze-thaw stability, solubility, heat inactivation, and inhibition by L-phenylalanine, L-homoarginine, and levamisole. The isoforms were also kinetically similar (i.e., maximal velocity and KM at pH 8.8 and pH 10.0). The isoforms differed, however, with respect to sensitivity to precipitation with wheat germ agglutinin (WGA), P < 0.001, but not Concanavalin A. At 3.0 mg/ml, WGA precipitated approximately 25% of B/I but more than 80% of B1 and B2. Molecular weights were estimated by native gradient gel electrophoresis: B/I, 126 kDa; B1, 136 kDa; and B2, 141 kDa. Desialylation with neuraminidase reduced the apparent sizes of B1 and B2 to 127 kDa (i.e., approximately to that of B/I). The total carbohydrate content was calculated to be 18 kDa, 28 kDa, and 33 kDa (i.e., 14%, 21%, and 23%) for the BALP isofonns, B/I, B1, and B2, respectively. The number of sialic acid residues was estimated to be 29 and 45, for each B1 and B2 homodimer, respectively. Apparent discrepancies between these estimates of molecular weight and estimates based on gel filtration chromatography were attributed to nonspecific interactions between carbohydrate residues and the gel filtration beads. All three BALP isoforms showed similar dose-dependent linearity in the commercial Alkphase-B and Tandem-MP Ostase immunoassays, r = 0.944 and r = 0.985, respectively (P < 0.001). In summary, our data indicate that B1 and B2 have more (or more reactive) sialic acid residues compared with B/I, which mainly explains the apparent differences in molecular weight. Future investigations will focus on the clinical and functional significance of the revealed differences in sialic acid residues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12232676     DOI: 10.1007/s00223-001-1137-4

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  12 in total

1.  Glycosylation differences contribute to distinct catalytic properties among bone alkaline phosphatase isoforms.

Authors:  Cecilia Halling Linder; Sonoko Narisawa; José Luis Millán; Per Magnusson
Journal:  Bone       Date:  2009-07-22       Impact factor: 4.398

2.  Elevated Alkaline Phosphatase in a Cancer Patient: Think You Know the Source?

Authors:  Brittany L Carroll; Martin Fleisher; Melissa S Pessin; Lakshmi V Ramanathan
Journal:  J Appl Lab Med       Date:  2017-11-01

3.  Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients.

Authors:  S Pilz; A Meinitzer; A Tomaschitz; K Kienreich; H Dobnig; M Schwarz; D Wagner; C Drechsler; C Piswanger-Sölkner; W März; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2012-03-17       Impact factor: 4.507

Review 4.  Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD.

Authors:  Mathias Haarhaus; Vincent Brandenburg; Kamyar Kalantar-Zadeh; Peter Stenvinkel; Per Magnusson
Journal:  Nat Rev Nephrol       Date:  2017-05-15       Impact factor: 28.314

5.  Isozyme profile and tissue-origin of alkaline phosphatases in mouse serum.

Authors:  Cecilia Halling Linder; Ulrika H Englund; Sonoko Narisawa; José Luis Millán; Per Magnusson
Journal:  Bone       Date:  2013-01-10       Impact factor: 4.398

6.  The novel bone alkaline phosphatase B1x isoform in children with kidney disease.

Authors:  Diana Swolin-Eide; Sverker Hansson; Lasse Larsson; Per Magnusson
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

Review 7.  Cellular function and molecular structure of ecto-nucleotidases.

Authors:  Herbert Zimmermann; Matthias Zebisch; Norbert Sträter
Journal:  Purinergic Signal       Date:  2012-05-04       Impact factor: 3.765

8.  Enhancement of drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide.

Authors:  Tatsuo Nishioka; Shunji Tomatsu; Monica A Gutierrez; Ken-ichi Miyamoto; Georgeta G Trandafirescu; Patricia L C Lopez; Jeffrey H Grubb; Rie Kanai; Hironori Kobayashi; Seiji Yamaguchi; Gary S Gottesman; Richard Cahill; Akihiko Noguchi; William S Sly
Journal:  Mol Genet Metab       Date:  2006-04-17       Impact factor: 4.797

9.  Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease Study.

Authors:  Christiane Drechsler; Barbara Kollerits; Andreas Meinitzer; Winfried März; Eberhard Ritz; Paul König; Ulrich Neyer; Stefan Pilz; Christoph Wanner; Florian Kronenberg
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

10.  Bone turnover markers in serum but not in saliva correlate with bone mineral density.

Authors:  Katharina Kerschan-Schindl; Ewald Boschitsch; Rodrig Marculescu; Reinhard Gruber; Peter Pietschmann
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.